Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

UCLA scientists identify clues to making immunotherapy more effective against glioblastoma

Two studies led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center provide insight into how the immune system can successfully be activated against glioblastoma while revealing why these therapies have historically fallen short.

October 16, 2026

Vol.52 No.38

Clinical Roundup

Wistar Institute study identifies immunotherapy strategy for glioblastoma

Scientists at the Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma. The researchers showed that reprogramming myeloid cells, a type of immune cell that glioblastoma tumors co-opt to protect themselves, while simultaneously boosting cancer-fighting T cells shrank the tumors and prevented them from coming back.

October 16, 2026

Vol.52 No.38

Drugs & Targets

FDA expands Anktiva approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease

FDA expanded the approved indication for Anktiva (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin to include patients with BCG-unresponsive NMIBC with papillary-only tumors.

October 16, 2026

Vol.52 No.38

Clinical Roundup

Urine test may improve bladder cancer diagnosis and guide treatment decision, Stanford-led study finds

A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose people with bladder cancer more accurately than current standard methods. The test also allows physicians to not only assess the cancer’s response to treatment but to predict whether immunotherapy or chemotherapy is likely to be most effective for each patient.

October 09, 2026

Vol.52 No.37

Clinical Roundup

Decipher prostate test predicts benefit from adding hormone therapy to radiation, phase III trial shows

Decipher Prostate Genomic Classifier can predict which patients are more likely to benefit from adding short-term ADT, or androgen deprivation therapy, to dose-escalated radiation, providing both Level 1B1 prognostic and predictive evidence, according to a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial.

October 02, 2026

Vol.52 No.36

Clinical Roundup

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Pancreatic tumors can resist immunotherapy by recruiting nearby immune cells to help protect them, according to researchers at The University of Texas at Austin. The findings, published in Nature Communications, also point to a potential new strategy for overcoming resistance and improving cellular therapies.

September 18, 2026

Vol.52 No.34

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

YOU MAY BE INTERESTED IN

UCLA scientists identify clues to making immunotherapy more effective against glioblastoma

Wistar Institute study identifies immunotherapy strategy for glioblastoma

FDA expands Anktiva approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease

Urine test may improve bladder cancer diagnosis and guide treatment decision, Stanford-led study finds

Decipher prostate test predicts benefit from adding hormone therapy to radiation, phase III trial shows

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Renew today!

Subscriber content

Never miss an issue!

Login